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New Oral Anticoagulants Are Not Superior to Warfarin in
Secondary Prevention of Stroke or Transient Ischemic
Attacks, but Lower the Risk of Intracranial Bleeding:
Insights from a Meta-Analysis and Indirect Treatment
Comparisons
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Abstract
Purpose: Patients with Atrial Fibrillation (AF) and prior stroke are classified as high risk in all risk stratification
schemes. A systematic review and meta-analysis was performed to compare the efficacy and safety of New Oral
Anticoagulants (NOACs) to warfarin in patients with AF and previous stroke or transient ischemic attack (TIA).
Methods: Three randomized controlled trials (RCTs), including total 14527 patients, comparing NOACs (apixaban,
dabigatran and rivaroxaban) with warfarin were included in the analysis. Primary efficacy endpoint was ischemic
stroke, and primary safety endpoint was intracranial bleeding. Random-effects models were used to pool efficacy and
safety data across RCTs. RevMan and Stata software were used for direct and indirect comparisons, respectively.
Results: In patients with AF and previous stroke or TIA, effects of NOACs were not statistically different from that of
warfarin, in reduction of stroke (Odds Ratio [OR] 0.86, 95% confidence interval [CI] 0.73- 1.01), disabling and fatal
stroke (OR 0.85, 95% CI 0.71-1.04), and all-cause mortality (OR 0.90, 95% CI 0.79 -1.02). Randomization to NOACs
was associated with a significantly lower risk of intracranial bleeding (OR 0.42, 95% CI 0.25-0.70). There were no
major differences in efficacy between apixaban, dabigatran (110 mg BID and 150 mg BID) and rivaroxaban. Major
bleeding was significantly lower with apixaban and dabigatran (110 mg BID) compared with dabigatran (150 mg BID)
and rivaroxaban.
Conclusion: NOACs may not be more effective than warfarin in the secondary prevention of ischemic stroke in
patients with a prior history of cerebrovascular ischemia, but have a lower risk of intracranial bleeding.
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Introduction

stroke varies between 2% and 15% in the first year, and 5%
yearly thereafter [4]. In patients with moderate to high-risk AF,
therapeutic anticoagulation has been shown to reduce the risk
of embolic phenomena and mortality [5]. Previous studies have
shown the beneficial effect of warfarin in the prevention of
stroke in AF, including patients with previous stroke or TIA [6].
However use of warfarin is associated with several limitations
including a narrow therapeutic range, need for coagulation

Patients with atrial fibrillation (AF) who have had a history of
previous stroke or transient ischemic attack (TIA) are at an
increased risk of recurrent stroke and or systemic embolism.
AF patients with prior cerebral ischemia are classified as high
risk by almost all stroke risk stratification schemes [1-3].
Following the initial attack of stroke, the recurrence rate of
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September 2012. We used the following Medical Subject
Heading terms and/or keywords: “new oral anticoagulants,”
“oral thrombin inhibitors,” “oral factor Xa inhibitors,”
“dabigatran,” “rivaroxaban,” “apixaban”. Clinical trial databases,
relevant reviews, and the reference lists of all retrieved reports
were manually searched for potentially relevant studies not
identified in our initial electronic database search.

monitoring, drug - food interactions, and an increased risk of
hemorrhage, including brain hemorrhage [6]. Newer drugs,
direct thrombin inhibitor dabigatran and factor Xa inhibitors
rivaroxaban and apixaban have been developed as an
alternative to warfarin. Recent trials have compared the
efficacy of these newer oral anticoagulants (NOACs) with
warfarin in patients with AF and previous history of stroke or
TIA [7-9].
A subgroup analysis of the RE-LY (Randomized Evaluation
of Long-Term Anticoagulation Therapy) trial has compared the
effects of dabigatran with warfarin in patients with atrial
fibrillation and previous stroke or TIA [7]. The study concluded
that in comparison to warfarin, 110 mg dabigatran was noninferior and 150 mg dabigatran was better in prevention of
stroke or systemic embolism. Another significant finding was
that 110 mg dabigatran caused less major bleeding and 150
mg dabigatran had similar rates of major bleeding compared to
warfarin. Subgroup analysis of ROCKET AF trial (Rivaroxaban
Once Daily Oral Direct Factor Xa Inhibitor Compared with
Vitamin K Antagonism for Prevention of Stroke and Embolism
Trial in Atrial Fibrillation) showed similar beneficial effect of
rivaroxaban in patients with or without previous stroke or TIA
[8]. Rivaroxaban (20 mg once daily) was non-inferior to
warfarin in the prevention of stroke and systemic embolism in
AF patients. The subgroup analysis of the ARISTOTLE
(Apixaban for Reduction in Stroke and Other Thromboembolic
Events in Atrial Fibrillation) analysis revealed that apixaban 5
mg twice daily was superior to warfarin for the prevention of
stroke or systemic embolism in AF patients with previous
stroke [9]. Apixaban was also associated with significantly less
major bleeding.
Although these trials suggested in favor of NOACs in
secondary prevention of stroke in patients with AF and
previous stroke and TIA, the reported efficacy outcomes and
safety outcomes were heterogeneous and also inconclusive on
few occasions. At the same time there is no previous or
ongoing, head-to-head trial among these NOACs. So the data
on relative efficacy and safety of NOACs, compared against
each other are very limited.
We systematically reviewed the data from randomized
controlled trials of the new oral anticoagulants in patients with
AF and previous stroke or transient ischemic attack. We
performed pooled direct comparisons with warfarin and indirect
comparisons among the NOACs on the efficacy and safety
outcomes data.

Study Selection
The PRISMA (Preferred Reporting Items for Systematic
reviews and Meta-Analyses) statement for reporting systematic
reviews and meta-analyses of RCTs [10] was used as a
reference method for this study. The studies were included if
they were RCTs, included atrial fibrillation patients with and
without previous history of stroke or TIA, randomized subjects
to warfarin and simultaneously to rivaroxaban, dabigatran, or
apixaban. We included both open-label and blinded studies, as
dose monitoring of warfarin makes blinding very difficult. To
assess the long-term efficacy and safety of NOACs, only RCTs
with long term follow-up (at least one year) were included in our
analysis.

Data Extraction and Quality Assessment
Two authors (PS, SC) reviewed the trials, ensured that they
met the inclusion criteria and abstracted the data. This was
checked for accuracy by the other authors and disagreements
were resolved by consensus (8% of the time). We performed
objective assessment of the trials using the method specified in
the Cochrane Handbook of Systematic Reviews—assessing for
randomization, allocation concealment, comparability of groups
at baseline, blinding, concomitant interventions, completeness
of follow-up and differential loss to follow-up, whether
incomplete data were addressed appropriately, validity of
outcome measures, and conflicts of interest.

Data Synthesis and Analysis
Outcome measures. The main efficacy outcome of interest
was an ischemic stroke. Other efficacy outcomes were stroke
or systemic embolism, hemorrhagic stroke, disabling and fatal
stroke and all-cause mortality. The main safety outcome of
interest was intracranial bleeding. Other safety outcomes were
major bleeding, and gastrointestinal bleeding.
Statistical analysis.
We performed direct pooled
comparisons between dabigatran, rivaroxaban, and apixaban
versus warfarin as well as indirect comparisons between the
three drugs (with warfarin as common comparator) on an
intention to treat basis. Odds Ratio (OR) and their respective
95% confidence intervals (CI) were estimated for each study
and for the analysis for each of the oral anticoagulants. We
assessed the heterogeneity using the Cochran Q test [11] and
the Higgins I2 test [12]. A Cochran’s Q P<0.10 and I2 >50%
were considered to show significant heterogeneity in this metaanalysis [12]. Random effects model described by DerSimonian and Laird was used for our main analysis [13]. We
also confirmed our results with use of a fixed effects model
described by Mantel Haenszel, in the absence of heterogeneity
[14]. We created funnel plots showing the standard error and
the effect size to evaluate publication bias, and also assessed

Methods
We systematically searched the published literature for trials
comparing any of the new oral anticoagulants (dabigatran,
rivaroxaban, and apixaban) with warfarin in patients with AF
and previous stroke and TIA.

Data Sources and Searches
The authors searched the PubMed, Cochrane CENTRAL,
EMBASE and CINAHL databases for English language, peerreviewed publications comparing NOACs with warfarin from
January 2001 (NOACs were introduced that year) through
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the same quantitatively with the regression test of Egger. Direct
comparisons were performed using the Review Manager
Version 5.1 (The Nordic Cochrane Center, The Cochrane
Collaboration, 2008, Copenhagen).
As a preferred method for indirect comparison, we used
Bucher’s method [15] for comparisons across the trials.
Bucher’s method estimates the comparative effectiveness of
two or more treatments by analyzing the extent of relative
treatment effects against a common comparator. The
application of this indirect comparison method is based on a
similarity assumption. Bucher’s method relies on the
assumption that the trials or subgroups within trials are
comparable in respect to clinical moderators (patient
characteristics, interventions, follow up periods) and
methodological moderators (randomization and blinding). We
used this approach to evaluate the relative efficacy and safety
of apixaban, dabigatran (110 mg & 150 mg), and rivaroxaban
using warfarin as common comparator.
To assess whether differences in trial methodology and
protocol, as well as patient characteristics affected the
outcomes, random-effects meta-regression analyses were
conducted. For indirect comparisons [Bucher’s method], and
meta-regression analyses we used the Stata 11.2SE
(StataCorp LP, College Station, Texas) software.
Figure 1. Search strategy and study selection as per
PRISMA checklist.

Results

doi: 10.1371/journal.pone.0077694.g001

A total of 2,560 reports were identified by our electronic
database search (Figure 1). Another 340 reports were also
identified through other sources. After removing duplicates,
non-relevant publications, and other reasons for exclusion as
mentioned in Figure 1, we accessed 36 full text articles for
eligibility. Finally, three trials involving total 14527 patients with
previous stroke or TIA met our inclusion criteria and were
included in the present analysis. All the trials were initially
reported with AF patients including all the risk groups [16-18].
Subsequently the data including the detailed sub-group
analysis of AF patients with previous stroke or TIA were
published [7-9]. For our analysis we included data from three
sub-group analyses of all three initial reports. The three
included trials assessed the relative efficacy and safety of new
oral anticoagulants, dabigatran, apixaban, or rivaroxaban
compared to warfarin in patients with AF and previous stroke or
TIA (Table 1).
These three trials randomized a total of 50578 atrial
fibrillation patients, including 14527 patients with previous
stroke or TIA. Of the patients with previous stroke and TIA,
5180 had TIA only. The average age of patients with previous
stroke and TIA ranged from 70.1 to 71 years, men constituted
61% to 64.1% of the study populations. In RE-LY and
ARISTOTLE trials >90% patients with previous stroke and TIA
had CHADS2≥3, and in ROCKET-AF trial median CHADS2
score was 4. The mean time in the therapeutic (TTR) range of
warfarin ranged from 57.1% to 65%. The prevalence of prior
diabetes and hypertension was highest in ROCKET-AF
compared with the other 2 trials. Prior warfarin use among
these high risk population was >60% in all three trials- RE-LY,
ROCKET-AF and ARISTOTLE. ROCKET-AF and RE-LY
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excluded patients with acute stroke within 14 days before
randomization, and ARISTOTLE excluded any stroke within 7
days before random assignment (Table 1 and Table 2). In each
trial, the new oral anticoagulants were found to be superior or
non-inferior to warfarin for the composite end point of stroke
and systemic embolism. The risk of hemorrhagic stroke was
lower with NOACs compared to warfarin. The definitions of
efficacy and safety outcomes are mentioned in Table S1.

Direct Comparisons
Efficacy outcomes. Efficacy analysis of NOACs compared
to warfarin in Atrial Fibrillation patients with previous history of
stroke or TIA, showed varied results (Figure 2). When data
were pooled across RCTs, No statistically significant difference
was found between NOACs and warfarin in the prevention of
primary outcome and two other important outcomes, for stroke
(Odds Ratio [OR] 0.86, 95% confidence interval [CI] 0.731.01), for disabling and fatal stroke (OR 0.85, 95% CI
0.71-1.04), and for all-cause mortality (OR 0.90, 95% CI 0.79
-1.02). In comparison to warfarin, NOACs only marginally
decreased stroke and systemic embolism (OR 0.85, 95% CI
0.74 -0.99). Compared to warfarin most significant beneficial
effect of NOACs was found in the prevention of hemorrhagic
stroke (OR 0.37, 95% CI 0.19-0.72).
Safety outcomes.
Randomization to NOACs were
associated with significantly lower risk for intracranial bleeding
(OR 0.42, 95% CI 0.25-0.70) (Figure 3). Major bleeding with
NOACs was similar as with warfarin (for AF with stroke and
TIA, OR 0.84, 95% CI 0.69 to 1.03). Use of NOACs was related
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Table 1. Study and patient characteristics (AF patients with previous stroke or TIA) of included randomized trials.

Trial
Study Characteristics

RE-LY

ROCKET AF

ARISTOTLE

3623(20%)

7468 (52%)

3436 (19%)

Total population in the study

18113

14264

18201

Mean TTR,%

63

57.1

65

Follow up periods

2.0 years[IQR 1.14 -2.86]

Median duration, 676 days (510-845)

1.8 years [IQR-1.4-2.3]

Prospective Randomized, open

Multicenter, randomized, double-blind, double-

Randomized control, double-blind,

label, blinded endpoint (PROBE)

dummy

parallel arm

TIA within 3 days, acute stroke within 14 days,

Patients with a previous intracranial

Stroke within 14 days or severe,

or severe disabling stroke (modified Rankin

hemorrhage (ICH) or any stroke

disabling stroke within 6 months

score 4–5, inclusive) within 3 months of

within 7 days before random

randomization

assignment

2561

956

Total (n) of Previous stroke or TIA (%of
total population)

Study Design

Stroke related exclusion Criteria

No of only previous TIA in stroke or TIA
group

1663

TIA: Transient Ischemic Attack
doi: 10.1371/journal.pone.0077694.t001

Table 2. Demographics and baseline clinical characteristics (Patients with previous stroke or TIA) of included randomized
controlled trials.

Characteristics

Trial
RE-LY

ROCKET AF

ARISTOTLE

Dabigatran 110

Dabigatran 150

Warfarin

Rivaroxaban

Warfarin

Total (n)

1195

1233

1195

3754

3714

3436

Age(years)

70.2(9.4)

70.8(10.1)

70.4(9.5)

71(64-76)

71(64-77)

70.1(9.5)

Men, %

64.1

62.2

62.4

61

61

63

CHADS2≥3, %

90.0

90.2

88.6

CHADS2 2, %

10.0

9.8

11.4

Median CHADS2 4(3-5)

Median CHADS2 4(3-5)

8

CHADS2 1, %

0

0

0

Vitamin K antagonist naïve, %

43.9

44

45.8

41

41

39

Diabetes,%

22.4

23.7

21.4

25

24

26

Hypertension,%

77

77.3

76.2

85

85

83

92
0

Table constructed as per available data in the included trials. For RE-LY and ARISTOTLE trial, Data are mean (SD) or number (%), if not specified. For ROCKET AF trial,
Data are median (IQR) or number (%), if not specified. TIA: Transient ischemic attack.
doi: 10.1371/journal.pone.0077694.t002

for apixaban versus dabigatran (110 mg BID and 150 mg BID)
or rivaroxaban; or rivaroxaban versus dabigatran (both doses)
in preventing stroke or systemic embolism (Table 3).
Hemorrhagic stroke was significantly less with dabigatran 110
mg BID in comparison to rivaroxaban (OR 0.15; 95% CI
0.03-0.67, p <0.0001), but not with 150 mg BID. For the
outcomes of stroke and disabling and fatal stroke, there were
no significant differences between the NOACs.
Relative
safety
of
dabigatran,
apixaban,
and
rivaroxaban. Major bleeding was significantly lower with
apixaban compared with dabigatran 150 mg BID (OR 0.19,
95% CI 0.13-0.28, p <0.0001) and rivaroxaban (OR 0.19, 95%
CI 0.14-0.28, p <0.0001), but was not significantly different
from dabigatran 110 mg BID (Table 3). Comparing with
rivaroxaban only Dabigatran 110 mg BID, was related to
significant less major bleeding (OR 0.68, 95%CI O.46-0.99,

to a statistically non-significant trend towards a higher rate of
gastrointestinal major bleeding compared to that of warfarin
(OR 1.17, 95% CI 0.76 to 1.80); these results may be
considered as inconclusive due to wide confidence intervals.
To account for the comparison of the 3-arm RE-LY trial [7]
for the 2 doses of dabigatran versus warfarin, we performed
separate analyses with each dose as a comparator of warfarin
in separate pooled analyses of the primary outcome (Figures 4
and 5). The separate analyses did not show substantial
differences with the original pooled outcomes (Figures 2 and
3).

Indirect Comparisons
Relative efficacy of dabigatran, apixaban, and
rivaroxaban. There were no significant differences in efficacy
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Figure 4. Forest plot comparing NOACs (including only
150 mg dabigatran) and warfarin for stroke (A) and
intracranial bleeding (B).
doi: 10.1371/journal.pone.0077694.g004

Figure 2. Forest plot(s) comparing NOACs and warfarin
in AF patients with previous stroke or TIA, for stroke (A),
disabling and fatal stroke(B), stroke and systemic
embolism (C), hemorrhagic stroke (D), and all-cause
mortality (E).

Figure 5. Forest plot comparing NOACs (including only
110 mg dabigatran) and warfarin for stroke (A) and
intracranial bleeding (B).

doi: 10.1371/journal.pone.0077694.g002

doi: 10.1371/journal.pone.0077694.g005

p=0.048), not dabigatran 150 mg BID. Dabigatran 110 mg BID
also had lower intracranial bleeding (OR 0.27, 95%CI
0.10-0.73, p=0.01) compared with rivaroxaban. Risk of
gastrointestinal major bleeding was similar with apixaban or
dabigatran.

Meta-Regression Analysis
To identify the impact of baseline variables and other factors
on the outcomes, meta-regression analysis was performed.
Mean TTR, mean age and percentage of male population,
explained fully the observed heterogeneity in the risk of stroke
and major bleeding, however other variables (percentage of
patients with diabetes, hypertension, CHF and follow up
duration) did not contribute to the heterogeneity (Figures 6 and
7).
There was also no significant publication bias detected with
examination of funnel plots or with Egger’s regression test for
primary outcomes (p=0.2). Risk of bias was objectively
assessed (Table 4).

Figure 3. Forest plot(s) comparing NOACs and warfarin
in AF patients with previous stroke or TIA, for major
bleeding (A), intracranial bleeding (B), and gastrointestinal
bleeding(C).
doi: 10.1371/journal.pone.0077694.g003
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Table 3. Indirect comparisons between apixaban, dabigatran and rivaroxaban with warfarin as single common comparator*.

Odd Ratio (95% CI)
Apixaban Vs Dabigatran

Apixaban Vs Dabigatran

Apixaban Vs

Dabigatran 110 Vs

Dabigatran 150 Vs

110

150

Rivaroxaban

Rivaroxaban

Rivaroxaban

Stroke or Systemic Embolism

0.9(0.56-1.47)

1.01(0.62-1.65)

0.81(0.55-1.18)

0.89(0.59-1.36)

0.8(0.52-1.22)

Hemorrhagic stroke

3.55(0.77-16.40)

1.44(0.44-4.77)

0.54(0.23-1.29)

0.15(0.03-0.67)

0.37(0.12-1.16)

Stroke

0.8(0.48-1.31)

0.93(0.56-1.55)

0.75(0.51-1.11)

0.95(0.61-1.46)

0.81(0.52-1.26)

Disabling and fatal stroke

1.07(0.58-2.00)

1.2(0.64-2.29)

0.93(0.55-1.58)

0.87(0.51-1.49)

0.77(0.45-1.34)

Major Bleeding

1.12(0.72-1.75)

0.19(0.13-0.28)

0.19(0.14-0.28)

0.68(0.46-0.99)

1.06(0.74-1.52)

Intracranial Hemorrhage

1.85(0.63-5.40)

0.9(0.37-2.22)

0.51(0.24-1.07)

0.27(0.10-0.73)

0.56(0.25-1.25)

0.49(0.23-1.05)

NA

NA

NA

Efficacy End Points

Safety end points

Gastrointestinal major bleeding 0.84(0.38-1.86)
* The bold indicate statistically significant values.
doi: 10.1371/journal.pone.0077694.t003

Discussion

systemic embolism and all cause mortality in comparison to
warfarin. Network meta-analysis showed that dabigatran and
apixaban were similarly superior to warfarin in prevention of
stroke or systemic embolism, but apixaban was related to less
major bleedings compared to dabigatran. In comparison to
warfarin, rivaroxaban did not reduce stroke or systemic
embolism and major bleedings, rivaroxaban was also
associated with excess major bleedings than apixaban.
Another network meta-analysis by Harenberg J et al [26]
showed, dabigatran (150 mg BID) had superior efficacy in
preventing
ischemic
stroke
or
systemic
embolism
than dabigatran (110 mg BID) and rivaroxaban.
We previously published the data on effectiveness of NOACs
for extended treatment of venous thromboembolism [27].
NOACs were effective for the long term treatment of venous
thromboembolism and might reduce the risk of all-cause
mortality. Our analysis also showed that dabigatran and
rivaroxaban may cause more major or clinically relevant
bleeding in this population [27]. Recently we evaluated the risk
of intracranial hemorrhage with NOACs in patients with atrial
fibrillation. Our analysis revealed, all the three individual
NOACs (dabigatran, rivaroxaban, apixaban) reduced the risk of
intracranial hemorrhage, Bayesian indirect comparison analysis
did not reveal a significant superiority of any specific
medications [28].
History of previous stroke is regarded as very high risk in all
Stroke Risk Stratification Schemes including CHA2DS2-VASc,
NICE (2006), ACC/AHA/ESC (2006), Framingham (2003),
CHADS2 (2001), ACCP (1998, 2001), SPAF (1995, 1998) and
AFI (1994) [1-3,29]. In the very popular CHADS2 score
scheme, 2 points (highest among all risk factors) is to be added
for a prior stroke or TIA. Subgroup Analysis of the RE-LY Trial
showed that higher CHADS2 scores were associated with
increased risks for stroke or systemic embolism, bleeding, and
death in patients with atrial fibrillation receiving newer or older
oral anticoagulants [30]. Recent analyses have shown that
NOACs have benefits over warfarin that is consistent across
patient risk of stroke as assessed by the CHADS2 score. A very
recent secondary analysis of the ARISTOTLE trial documented
that apixaban significantly reduced stroke or systemic

In this systematic review and meta-analysis we found that
compared to warfarin, the effectiveness of NOACs over that of
warfarin, is not consistent in patients with AF and previous
stroke or TIA. Our indirect comparison analysis shows that
there were no significant efficacy differences between
apixaban, dabigatran (150 mg BID), or rivaroxaban in patients
with previous stroke. Dabigatran 110 mg BID caused less
hemorrhagic stroke compared to rivaroxaban. In clinical
practice, patients with AF and previous stroke or TIA are
common and previous studies revealed that these patients
have higher risk of death and other complications [1,19].
A number of recent reviews of efficacy and safety of New
Oral Anticoagulants are available based on the initial RELY,
ROCKET-AF and ARISTOTLE trial [16-18,20-22]. The newer
oral anticoagulants were found to be more efficacious or noninferior than warfarin for the prevention of stroke or systemic
embolism and other outcomes in patients with AF (including all
risk factors). Direct comparison analysis by Miller CS et al [20],
showed patients randomized to NOACs had a decreased risk
for all-cause stroke and systemic embolism, ischemic stroke,
all-cause mortality and intracranial bleeding, however data
regarding the risks for major bleeding and gastrointestinal
bleeding were inconclusive. Similar results were also reported
by Dogliotti A et al [21]. Adam SS et al, also reported less allcause mortality with NOACs [22]. Meta-analysis by Kwong JS
et al, including data from 13 studies showed NOACs are more
effective in reducing stroke and systemic embolism without
increasing the risk of major bleeding compared to conventional
oral anticoagulants [23]. Dentali F et al, meta-analyzed data
from 12 studies and showed, NOACs significantly reduced allcause mortality, cardiovascular mortality, and stroke or
systemic embolism. Analysis for safety outcomes showed,
there was a trend toward less major bleeding and a significant
reduction of intracranial hemorrhage with NOACs [24].
Efficacy and safety of NOACs also have been evaluated in
recent network meta-analyses. A pair-wise and warfarincontrolled network meta-analyses by Biondi-Zoccai G et al [25]
showed that after a weighted average of 23 months of follow
up, NOACs lead to significant reductions in the risk of stroke or
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Figure 7. Meta-regression analysis for major bleeding
(with following variables- mean time in therapeutic range,
mean age, percentage of male population, percentage of
patients with diabetes, hypertension, congestive heart
failure and follow up duration).

Figure 6. Meta-regression analysis for stroke (with
following variables- mean time in therapeutic range, mean
age, percentage of male population, percentage of patients
with diabetes, hypertension, congestive heart failure and
follow up duration).

doi: 10.1371/journal.pone.0077694.g007

doi: 10.1371/journal.pone.0077694.g006

RELY, ROCKET-AF or ARISTOTLE did not include very low
risk patients (for stroke). Though the NOACs may have some
benefit over warfarin in very high risk patients (patients with AF
and previous stroke), but our findings did not show any benefit
of NOACs in secondary prevention of ischemic stroke.
Limitations aside, our meta-analysis emphasizes the need for
future randomized trials focusing on the use of NOACs in AF
patients with previous stroke.

embolism and other outcomes, with no evidence of a
differential effect by risk of stroke [31].
Interestingly, in our analysis we found that in comparison to
warfarin, efficacy of NOACs in patients with AF and previous
stroke or TIA is not consistent. NOACs are recommended by
previous trials for use in moderate to high risk patients with
previous stroke, not with very low risk patients, because all of
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dabigatran (110 mg BID). This drug may be a potential choice
in this high risk group. But currently FDA has approved only
150 mg and 75 mg of dabigatran in the USA, and efficacy of
dabigatran 75 mg BID has not been assessed in these high risk
patients. There are also recent concerns regarding significant
bleeding events and myocardial infarction with the use of
dabigatran [36]. In this context, the risk vs. benefit of low dose
dabigatran in this population should be interpreted cautiously.

Table 4. Risk of bias assessments for included studies.

RE-LY

ROCKET-AF ARISTOTLE

Low

Low

Low

Low

Low

Low

Unclear Low

Low

Low

Low

Low

Incomplete outcome data (attrition bias)

Low

Low

Low

Selective reporting (reporting bias)

Low

Low

Low

Other bias

Low

Low

Low

Random sequence generation (selection
bias)
Allocation concealment (selection bias)
Blinding of participants and researchers
(performance bias)
Blinding of outcome assessment (detection
bias)

Study Limitations
Our present study has potential limitations. We included data
from the subgroup analyses of initial trials, which may introduce
analytic challenges [37]. Our meta-regression analysis
revealed the impact of differences in patient characteristics on
clinical outcomes. ROCKET-AF included a comparatively
higher risk population. Patients of the warfarin group in
ROCKET-AF had much less ‘mean time in therapeutic range’
than that of RE-LY and ARISTOTLE trials, which is difficult to
adjust for (although we did not find a significant association
with our meta-regression). Our analysis also cannot directly
evaluate the effects of NOACs, for the patients who have a
stroke while on-treatment with warfarin. Most of the outcomes
are in the borderline zone, so that should be interpreted very
cautiously. Studies with edoxaban, another NOAC was not
included in the analysis-due to non-availability of the data.
NOACs are chemically different compounds, and dabigatran
which is a direct thrombin inhibitor is a different group of
medication compared to factor Xa inhibitors (rivaroxaban and
apixaban). So, there are concerns regarding the pooling of data
for these compounds. However, this method of data pooling is
an acceptable approach and several meta-analysis have been
published recently with pooled analysis including these three
NOACs [22–24]. Data pooling across studies increases the
power of the analysis, permits a full examination of effect
modification within the data and adds robustness to the results
obtained [22].
As per the International Society for Pharmacoeconomics and
Outcomes Research (ISPOR), recommendations and
guidelines, in the absence of RCTs involving a direct
comparison of all treatments of interest, an indirect treatment
comparison provides useful information [38]. However, indirect
comparison analysis has its limitations, most importantly, the
failure of the assumptions of similarity and consistency may
render results questionable [32,38].

doi: 10.1371/journal.pone.0077694.t004

In our analysis, the risk of major bleeding was comparable
between and NOACs and warfarin, and, gastrointestinal major
bleeding was higher (the results to be interpreted cautiously
due to wide CI) in patients with NOACs compared to warfarin.
Similar findings were also reported previously [22,23].
Recent indirect comparison analyses, including data from
initial RELY, ROCKET-AF and ARISTOTLE trials concluded
that – the relative efficacy of new anticoagulants are not
profoundly different [32-34]. These analyses showed
dabigatran 150 mg BID was superior to rivaroxaban for the
efficacy endpoints of stroke or systemic embolism. The risk of
major bleeding was significantly lower with dabigatran 110 mg
BID or apixaban. An analysis by Baker WL et al showed
apixaban lowered the risk of major bleeding and
gastrointestinal bleeding compared to dabigatran [34].
Compared to rivaroxaban, apixaban decreased the risk of
major bleeding, but increased the risk of systemic emboli [34].
These analyses did not consider the separate analyses of the
subgroup of patients with previous stroke. In our analysis we
also found protective effects of apixaban or dabigatran 110 mg
BID in the prevention of major bleeding, but there was no
difference between Dabigatran 150 mg BID and rivaroxaban in
efficacy endpoints in AF patients with a previous stroke or TIA.
A recently published meta-analysis (classical network meta
analysis) indirectly compared the new oral anticoagulant drugs
for primary and secondary prevention of stroke in atrial
fibrillation [35]. They found beneficial effects of dabigatran 110
mg BID over rivaroxaban in secondary prevention for
hemorrhagic stroke, vascular death, major bleeding, and
intracranial bleeding. On the other hand, the main objective of
our study was to compare the efficacy of NOACs and warfarin
in the secondary prevention of stroke. As mentioned earlier,
our analysis revealed that in prevention of ischemic stroke,
NOACs are not better than warfarin in this high risk population,
but may be safer especially for the risk of ICH. This important
message is missing in that article. We also found a beneficial
effect of apixaban compared to rivaroxaban and dabigatran
150 mg BID for the risk of major bleeding.
In our analysis, the only meaningful finding in support of use
of NOACs in AF with previous stroke was significant reduction
of hemorrhagic stroke and intracranial bleeding. But careful
interpretation revealed that this benefit is limited to low dose

PLOS ONE | www.plosone.org

Conclusion
Based on available trials data, no major differences in the
efficacy between warfarin and NOACs were found in AF
patients with a previous stroke or TIA. But pooled analysis
revealed a lower risk of ICH with use of NOACs. The relative
effects of apixaban, dabigatran (both doses) and rivaroxaban
are not significantly different in AF patients with a previous
stroke or TIA. Randomized clinical trials focusing on this high
risk group and head-to-head real-world direct comparison of
the different NOACs are required to properly recognize the
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